Skip to main content
Top
Published in: Lung 5/2017

01-10-2017

A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis

Authors: G. E. Carpagnano, R. Santacroce, G. A. Palmiotti, A. Leccese, E. Giuffreda, M. Margaglione, M. P. Foschino Barbaro, S. Aliberti, D. Lacedonia

Published in: Lung | Issue 5/2017

Login to get access

Abstract

Alpha-1-antitrypsin deficiency (AATD) is a genetic condition caused by SERPINA1 mutations, which culminates into lower protease inhibitor activity in the serum and predisposes to emphysema. Clinical manifestations of AATD are often associated to ZZ (p.Glu342Lys) and SZ (p.Glu264Val) genotypes and less frequently to rare deficiency or null alleles in heterozygous and homozygous states. We report a case of a 52-year-old woman with bronchiectasis without other potential causes other than an electrophoresis that showed a decrease of alpha-1 globin band and AAT levels below the normal value (78 mg/dl; v.n. 90–200 mg/dl). No S or Z mutation was identified, but sequencing analysis found a novel missense variant Ile74Asn (c.221T > A) in heterozygous state on an M3 allele (Glu400Asp) in the exon 2 of the SERPINA-1gene, probably leading to a dysfunctional protein. This mutation has never been previously identified, and it is interesting to note the association with bronchiectasis in the absence of emphysema.
Literature
1.
go back to reference Blanco I, de Serres F, Fernandez-Bustillo E et al (2006) Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 27:77–78CrossRefPubMed Blanco I, de Serres F, Fernandez-Bustillo E et al (2006) Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 27:77–78CrossRefPubMed
2.
go back to reference Silverman E, Sandhaus R (2009) Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 360:2749–2757CrossRefPubMed Silverman E, Sandhaus R (2009) Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 360:2749–2757CrossRefPubMed
3.
go back to reference Demeo DL, Silverman EK (2004) Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 59(3):259–264CrossRefPubMedPubMedCentral Demeo DL, Silverman EK (2004) Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 59(3):259–264CrossRefPubMedPubMedCentral
4.
go back to reference Greulich T, Nell C, Herr C et al (2016) Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003–2015. Orphanet J Rare Dis. 11(1):75CrossRefPubMedPubMedCentral Greulich T, Nell C, Herr C et al (2016) Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003–2015. Orphanet J Rare Dis. 11(1):75CrossRefPubMedPubMedCentral
5.
go back to reference Greulich T, Averyanov A, Borsa L et al (2017) European screening for alpha-1 antitrypsin deficiency in subjects with lung disease. Clin Respir J 11(1):90–97CrossRefPubMed Greulich T, Averyanov A, Borsa L et al (2017) European screening for alpha-1 antitrypsin deficiency in subjects with lung disease. Clin Respir J 11(1):90–97CrossRefPubMed
6.
go back to reference Elliott PR, Pei XY, Dafforn TR et al (2000) Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 9(7):1274–1281CrossRefPubMedPubMedCentral Elliott PR, Pei XY, Dafforn TR et al (2000) Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 9(7):1274–1281CrossRefPubMedPubMedCentral
7.
go back to reference Frazier GC, Siewertsen MA, Hofker MH et al (1990) A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. Clin Investig 86(6):1878–1884CrossRef Frazier GC, Siewertsen MA, Hofker MH et al (1990) A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. Clin Investig 86(6):1878–1884CrossRef
8.
go back to reference Parr DG, Guest PG, Reynolds JH et al (2007) Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 176:1215–1221CrossRefPubMed Parr DG, Guest PG, Reynolds JH et al (2007) Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 176:1215–1221CrossRefPubMed
9.
go back to reference Scott JH, Anderson CL, Shankar PS et al (1977) Alpha1-antitrypsin deficiency with diffuse bronchiectasis and cirrhosis of the liver. Chest 71:535–538CrossRefPubMed Scott JH, Anderson CL, Shankar PS et al (1977) Alpha1-antitrypsin deficiency with diffuse bronchiectasis and cirrhosis of the liver. Chest 71:535–538CrossRefPubMed
10.
go back to reference Milger K, Holdt LM, Teupser D et al (2015) Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. Int J Chron Obstruct Pulmon Dis. 7(10):891–897CrossRef Milger K, Holdt LM, Teupser D et al (2015) Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism. Int J Chron Obstruct Pulmon Dis. 7(10):891–897CrossRef
11.
go back to reference Lonni S, Chalmers JD, Goeminne PC et al (2015) Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 12(12):1764–1770CrossRefPubMedPubMedCentral Lonni S, Chalmers JD, Goeminne PC et al (2015) Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc 12(12):1764–1770CrossRefPubMedPubMedCentral
12.
go back to reference Clemmensen SN, Jacobsen LC, Rørvig S et al (2011) Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis. Eur J Haematol 86:517–530CrossRefPubMed Clemmensen SN, Jacobsen LC, Rørvig S et al (2011) Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis. Eur J Haematol 86:517–530CrossRefPubMed
13.
14.
go back to reference Stockley RA, Parr DG, Piitulainen E et al (2010) Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomized clinical trials using computed tomography densitometry. Respir Res 11:136CrossRefPubMedPubMedCentral Stockley RA, Parr DG, Piitulainen E et al (2010) Therapeutic efficacy of α-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomized clinical trials using computed tomography densitometry. Respir Res 11:136CrossRefPubMedPubMedCentral
15.
go back to reference Stockley RA, Bayley DL, Unsal I et al (2002) The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 165(11):1494–1498CrossRefPubMed Stockley RA, Bayley DL, Unsal I et al (2002) The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 165(11):1494–1498CrossRefPubMed
16.
go back to reference Lieberman J (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 118(5):1480–1485CrossRefPubMed Lieberman J (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 118(5):1480–1485CrossRefPubMed
17.
go back to reference Wanner A, Arce AD, Pardee E (2012) Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD 9(6):583–588CrossRefPubMed Wanner A, Arce AD, Pardee E (2012) Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD 9(6):583–588CrossRefPubMed
Metadata
Title
A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis
Authors
G. E. Carpagnano
R. Santacroce
G. A. Palmiotti
A. Leccese
E. Giuffreda
M. Margaglione
M. P. Foschino Barbaro
S. Aliberti
D. Lacedonia
Publication date
01-10-2017
Publisher
Springer US
Published in
Lung / Issue 5/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-017-0033-2

Other articles of this Issue 5/2017

Lung 5/2017 Go to the issue